XML 70 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Collaboration and License Agreements (Details)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
geneTherapyProgram
$ / shares
shares
Sep. 30, 2024
USD ($)
non-clinicalStageCompound
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
undisclosedProgram
preclinicalCandidate
$ / shares
shares
Jun. 30, 2025
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Acquired in-process research and development $ 1.0     $ 0.0   $ 9.5 $ 143.9        
Total revenues 622.1     498.8   1,727.6 1,371.9        
Collaborative Arrangement | Common Stock | Voyager                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Beneficial ownership (as a percent)         19.90%            
Nxera | Collaborative Arrangement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Research and development 35.0 $ 15.0                  
Potential milestone payments 2,600.0         $ 2,600.0          
Agreement termination, minimal contractual time (in days)           180 days          
Agreement termination, contractual time threshold (in days)           90 days          
Agreement termination by counterparty, contractual time threshold (in days)           365 days          
Agreement termination by counterparty, minimal contractual time (in days)           120 days          
Nxera | Collaborative Arrangement | Forecast                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Potential milestone payments                     $ 15.0
Takeda | Collaborative Arrangement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Research and development   7.5                  
Potential milestone payments 1,900.0         $ 1,900.0          
Agreement termination, minimal contractual time (in days)           6 months          
Agreement termination, contractual time threshold (in days)           12 months          
Number of non-clinical stage compounds | non-clinicalStageCompound           3          
Idorsia | Collaborative Arrangement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Potential milestone payments 1,700.0         $ 1,700.0          
Agreement termination, minimal contractual time (in days)           90 days          
Agreement termination, due to material breach (in days)           90 days          
Xenon | Collaborative Arrangement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Potential milestone payments 1,700.0         $ 1,700.0          
Agreement termination, contractual time threshold (in days)           90 days          
Number of preclinical candidates | preclinicalCandidate                   3  
Share price (in USD per share) | $ / shares               $ 31.855 $ 19.9755 $ 14.196  
Equity securities fair value (Level 3)                 $ 4.6 $ 14.1  
Equity securities fair value (Level 1)               $ 7.7      
Xenon | Collaborative Arrangement | Common Stock                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Sale of stock (in shares) | shares               0.3 0.3 1.4  
Voyager | Collaborative Arrangement | Common Stock                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Sale of stock (in shares) | shares         4.4         4.2  
Transfer, beneficial ownership, and voting restrictions period (in years)         3 years            
2019 Voyager Agreement | Collaborative Arrangement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Research and development     $ 5.0                
Potential milestone payments 1,300.0         $ 1,300.0          
Agreement termination, minimal contractual time (in days)           180 days          
Agreement termination, contractual time threshold (in days)           1 year          
Share price (in USD per share) | $ / shares                   $ 11.9625  
Equity securities fair value (Level 3)                   $ 54.7  
Number of undisclosed programs | undisclosedProgram                   2  
2023 Voyager Agreement | Collaborative Arrangement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Research and development 3.0 $ 3.0                  
Potential milestone payments 6,100.0         $ 6,100.0          
Agreement termination, minimal contractual time (in days)           180 days          
Agreement termination, contractual time threshold (in days)           1 year          
Share price (in USD per share) | $ / shares         $ 8.88            
Equity securities fair value (Level 1)         $ 31.3            
Number of gene therapy programs | geneTherapyProgram         3            
Upfront payment         $ 175.0            
Board of directors maximum duration term (in years)         10 years            
Acquired in-process research and development         $ 143.9            
MTPC | Collaborative Arrangement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Agreement termination, contractual time threshold (in days)           180 days          
Potential milestone payment receipts 30.0         $ 30.0          
MTPC | Collaborative Arrangement | Minimum | Patents                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Patent term (in years)           10 years          
AbbVie | Collaborative Arrangement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Agreement termination, contractual time threshold (in days)           180 days          
Potential milestone payment receipts 366.0         $ 366.0          
AbbVie | Collaborative Arrangement | Royalty                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Total revenues $ 3.3     $ 4.2   $ 9.8 $ 12.0        
AbbVie | Collaborative Arrangement | Minimum | Patents                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Patent term (in years)           10 years